Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: Incremental value of magnetic resonance imaging for prediction of disease reclassification

Journal of Computer Assisted Tomography

Volumn 37, Issue 6, 2013, Pages 948-956

  Bonekamp, David ^a   Bonekamp, Susanne ^a   Mullins, Jeffrey K ^a   Epstein, Jonathan I ^a   Carter, H Ballentine ^a   Macura, Katarzyna J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

active surveillance; disease reclassification; index lesion; multiparametric MRI; prostate cancer

Indexed keywords

DISEASES; MAGNETISM; MONITORING; RESONANCE; UROLOGY;

ACTIVE SURVEILLANCE; CLINICAL PARAMETERS; DISEASE RECLASSIFICATION; FOLLOW UP; IMAGING BIOMARKERS; INDEX LESION; MORPHOLOGICAL PARAMETERS; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUES; PROSTATE CANCERS;

MAGNETIC RESONANCE IMAGING;

GADOLINIUM PENTETATE MEGLUMINE; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE RECLASSIFICATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE DISEASE; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TUMOR BIOPSY;

EID: 84889027505     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0b013e31829ae20a     Document Type: Article

References (28)

1. Ukimura O, Faber K, Gill IS. Intraprostatic targeting. Curr Opin Urol. 2012;22:97-103
2. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: Review of the current literature. Cancer. 2008;112:1650-1659
3. Catalona WJ. Editorial comment. J Urol. 2009;182:2278-2279; discussion 2279
4. Duffield AS, Lee TK, Miyamoto H, et al. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009;182:2274-2278
5. Barocas DA, Cowan JE, Smith JA, Jr., et al. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008;180:1330-1334; discussion 1334-1335
6. Berglund RK, Masterson TA, Vora KC, et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180:1964-1967; discussion 1967-1968
7. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719
8. Griffin CR, Yu X, Loeb S, et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol. 2007;178:860-863; discussion 863
9. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46-50
10. Marberger M, Barentsz J, Emberton M, et al. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int. 2012;109(suppl 2):1-7
11. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol. 2012;188: 1732-1738
12. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374
13. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185-2190
14. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw. 2010;8:162-200
15. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/ dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172
16. Morgan VA, Riches SF, Thomas K, et al. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance. Br J Radiol. 2011;84:31-37
17. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol. 2009;56: 981-987
18. deSouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: A potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol. 2008;63:774-782
19. Nagarajan R, Margolis D, Raman S, et al. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging. 2012;36:697-703
20. Hong MK, Namdarian B, Corcoran NM, et al. Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology. 2011;43:138-142
21. Mouraviev V, Villers A, Bostwick DG, et al. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy. BJU Int. 2011;108:1074-1085
22. Margel D, Yap SA, Lawrentschuk N, et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: A prospective cohort study. J Urol. 2012;187:1247-1252
23. Fradet V, Kurhanewicz J, Cowan JE, et al. Prostate cancer managed with active surveillance: Role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 2010;256:176-183
24. Shukla-Dave A, Hricak H, Akin O, et al. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int. 2012;109:1315-1322
25. Puech P, Potiron E, Lemaitre L, et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology. 2009;74:1094-1099
26. Villeirs GM, De Meerleer GO, De Visschere PJ, et al. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol. 2011;77:340-345
27. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131
28. Vargas HA, Akin O, Shukla-Dave A, et al. Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: A prospective study. Radiology. 2012;265:478-487